Closely monitor patients for any anginal symptoms (eg, chest pain). Not to be administered to patients w/ cerebral infraction until condition is stabilized. Discontinue use or dosage reduction if excessive increase in pulse rate is observed in patients w/ coronary artery stenosis. Risk of menorrhagia in patients during menstruation. Patients w/ bleeding tendency or predisposition to bleeding, coronary artery stenosis, DM or abnormal glucose tolerance, severe HTN w/ consistently high BP eg, malignant HTN. Patients on anticoagulants (eg, warfarin), antiplatelets (eg, aspirin or ticlopidine), thrombolytics (eg, urokinase or alteplase), or prostaglandin E
1 or its derivatives (eg, alprostadil). Monitor patients for development of new systolic murmur or cardiac symptoms after starting treatment. Severe hepatic & severe renal impairment. Lactation. Childn. Elderly.
Sign Out
